Meyahealth
HomeGeneticsConditionGaucher disease
Back to Condition
Gaucher disease
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Gaucher disease

Gaucher disease is an inherited disorder caused by the buildup of fatty substances in organs and tissues, leading to a wide range of symptoms depending on the type.

Overview

Gaucher disease is an inherited disorder that affects many of the body's organs and tissues. The signs and symptoms of this condition vary widely among affected individuals, and researchers have described several types based on their characteristic features.

Types and Symptoms

  • Type 1 (Non-neuronopathic): The most common form, where the brain and spinal cord are usually not affected. Symptoms include enlargement of the liver and spleen (hepatosplenomegaly), a low number of red blood cells (anemia), easy bruising due to low blood platelets (thrombocytopenia), bone pain, fractures, and arthritis.
  • Types 2 and 3 (Neuronopathic): Characterized by problems affecting the central nervous system, including abnormal eye movements, seizures, and brain damage. Type 2 causes life-threatening problems in infancy, while Type 3 tends to worsen more slowly.
  • Perinatal Lethal Form: A rare, severe form of Type 2. Features include fluid accumulation before birth (hydrops fetalis), dry/scaly skin (ichthyosis), hepatosplenomegaly, and serious neurological problems. Most infants survive only a few days.
  • Cardiovascular Type (Type 3c): Primarily affects the heart, causing heart valves to harden (calcify). It may also involve eye abnormalities, bone disease, and mild spleen enlargement.

Frequency

Gaucher disease occurs in 1 in 50,000 to 100,000 people. Type 1 is most common in Europe, Israel, Canada, and the United States, particularly among those of Ashkenazi Jewish heritage, affecting 1 in 500 to 1,000 individuals in that population.

Causes

Variants (mutations) in the GBA1 gene cause Gaucher disease. This gene provides instructions for making the enzyme lysosomal acid glucosylceramidase, which breaks down the fatty substance glucocerebroside. Variants in GBA1 reduce or eliminate this enzyme's activity, causing toxic levels of glucocerebroside to build up within cells.

Inheritance

This condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have variants.

Frequently Asked Questions

If one partner carries a pathogenic GBA1 mutation, the child’s risk is 0 % for classic Gaucher disease unless the other partner also carries a mutation. Carrier testing of the other partner clarifies the risk. If both are carriers, each pregnancy has a 25 % chance of an affected child (autosomal recessive). Pre‑conception genetic counseling and, if desired, pre‑implantation genetic testing can be used.
Bone health should be assessed at baseline and then every 12‑24 months with a combination of dual‑energy X‑ray absorptiometry (DEXA) for density, MRI of the femur and lumbar spine for marrow infiltration, and plain X‑rays if pain or fractures occur. Early MRI can detect asymptomatic osteonecrosis, guiding treatment adjustments.
Yes, most studies show that continuing ERT during pregnancy is safe for both mother and fetus and helps control organ size, anemia, and platelet counts. However, dosing may need adjustment, and close monitoring by a multidisciplinary team (obstetrics, genetics, hematology) is recommended.
Enzyme replacement therapy (ERT) with imiglucerase, velaglucerase alfa, or taliglucerase alfa is the first‑line treatment for symptomatic organ enlargement, anemia, thrombocytopenia, or bone disease. Substrate reduction therapy (SRT) with eliglustat or miglustat is an oral alternative for patients who cannot tolerate ERT or have mild disease. Choice depends on disease severity, age, organ involvement, and patient preference.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ